<DOC>
	<DOCNO>NCT00000813</DOCNO>
	<brief_summary>Part A : To evaluate safety immunogenicity ALVAC vCP125 HIV-1 gp160 MN live canarypox recombinant vaccine ( ALVAC gp160 MN ) versus recombinant canarypox express rabies glycoprotein ( ALVAC rabies glycoprotein ) control healthy , HIV-1 uninfected adult volunteer . Part B : To evaluate schedule two immunization ALVAC gp160 MN optimal immunogenicity . Amendment : 12/22/93 : To determine whether ALVAC gp160 MN combination SF-2 rgp120 subunit protein capable generate humoral cellular immune response great intensity long duration either vaccine administer alone . A canarypox-vectored vaccine ( ALVAC ) express gp160 antigen HIV-1 MN strain might satisfy many criterion affordable HIV vaccine . Per 12/22/93 amendment : Cellular response augment combination two recombinant vaccine , especially vaccinia naive individual .</brief_summary>
	<brief_title>A Phase I Safety Immunogenicity Trial Live Recombinant Canarypox-gp160 MN ( ALVAC vCP125 , HIV-1 gp160 MN ) HIV-1 Uninfected Adult Volunteers</brief_title>
	<detailed_description>A canarypox-vectored vaccine ( ALVAC ) express gp160 antigen HIV-1 MN strain might satisfy many criterion affordable HIV vaccine . Per 12/22/93 amendment : Cellular response augment combination two recombinant vaccine , especially vaccinia naive individual . In Part A , 28 healthy volunteer ( 15 vaccinia-immune 13 vaccinia-naive ) randomize receive intramuscular injection ALVAC gp160 MN dose 1 million TCID50 ALVAC rabies glycoprotein control month 0 2 . In Part B , 90 healthy volunteer ( 60 vaccinia immune 30 vaccinia naive ) randomize receive ALVAC gp160 MN dose 10 million TCID50 ALVAC rabies glycoprotein control , immunization schedule either month 0 1 0 2 . For Part B , half patient receive ALVAC gp160 MN , well approximately half receive control vaccine , receive booster immunization SF-2 rgp120 subunit protein , available , month 9 12 ; half receive booster immunization preparation receive first two immunization . In Part A , control volunteer except one within control group receive SF-2 rgp120 subunit protein month 9 12 . An additional group 10 volunteer receive four injection SF-2 rgp120 subunit protein month 0 , 1 , 6 12 . Part B begin whenever high dose ALVAC gp160 MN become available ( least 4 week initiation Part A ) . Volunteers follow least 18 month . Per 06/10/94 addendum , volunteer contact twice per year least 5 year check health status .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Inclusion Criteria Subjects must : Normal history physical exam . Negative ELISA HIV . CD4 count &gt; = 400 cells/mm3 . Normal urine dipstick esterase nitrite . Lower risk sexual behavior . NOTE : No 10 percent participant older 50 year . Prior Medication : Allowed : Prior smallpox vaccination . Exclusion Criteria Coexisting Condition : Subjects follow symptoms condition exclude : Positive hepatitis B surface antigen . Medical psychiatric condition ( recent suicidal ideation present psychosis ) preclude compliance . Occupational responsibility preclude compliance . Active syphilis . NOTE : Subjects serology document false positive due remote ( &gt; 6 month ) treat infection eligible . Active tuberculosis . NOTE : Subjects positive PPD normal chest xray show evidence TB require isoniazid therapy eligible . Allergy egg product neomycin . Occupational exposure bird . Subjects follow prior condition exclude : History immunodeficiency , chronic illness , autoimmune disease , use immunosuppressive medication . History anaphylaxis serious adverse reaction vaccine . Prior immunization rabies . History serious allergic reaction substance , require hospitalization emergent medical care ( e.g. , StevensJohnson syndrome , bronchospasm , hypotension ) . Prior psychiatric condition ( history suicide attempt past psychosis ) preclude compliance . History cancer unless surgical excision consider achieved cure . Prior Medication : Excluded : Live attenuate vaccine within 60 day prior study entry . NOTE : Medically indicate kill subunit vaccine ( e.g. , influenza , pneumococcal ) exclude administer least 2 week HIV immunization . Experimental agent within 30 day prior study entry . Prior HIV vaccine . Prior rabies immunization . Prior Treatment : Excluded : Blood product immunoglobulin within 6 month prior study entry . It STRONGLY RECOMMENDED activity might expose subject HIV ( unprotected sex needle share ) avoid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>HIV Envelope Protein gp160</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Avipoxvirus</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>